RT Journal Article
SR Electronic
T1 68Ga-DOTATOC PET/CT in the monitoring of 90Y-DOTATOC treatment
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 1656
OP 1656
VO 50
IS supplement 2
A1 Versari, Annibale
A1 Fraternali, Alessandro
A1 Frasoldati, Andrea
A1 Carpi, Amalia
A1 Asti, Mattia
A1 Filice, Angelina
A1 Di Paolo, Maria Liberata
A1 Fioroni, Federica
A1 Giunta, Francesca
A1 Calandri, Enrico
YR 2009
UL http://jnm.snmjournals.org/content/50/supplement_2/1656.abstract
AB 1656 Objectives Aim of this study is to evaluate the role of 68Ga-DOTATOC PET/CT in monitoring the radiolabelled somatostatin analog 90Y-DOTA-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) treatment. Methods Forty patients (pts), m/f 20/20, age 32-83 yrs, mean 66 yrs, with metastatic somatostatin-receptor-positive tumors, were treated with 90Y-DOTATOC (31 NETs, 4 radioiodine negative differentiated thyroid carcinoma, 4 small-cell lung carcinoma, 1 breast cancer). Pts underwent 68Ga-DOTATOC PET/CT before therapy and 2 months after each treatment. PET studies were compared by visual and SUV analysis. Response was documented also by clinical and biochemical findings. Treatment was once every 3 months. Results Two pts had 6 treatments, 13 pts 5, 5 pts 4, 3 pts 3, 10 pts 2 and 7 pts 1. The responses were as follows: 18% progression disease, 43% stable disease, 21% partial response and 3% complete response; in 6 pts (15%) the evaluation is in progress. The clinical response resulted higher than biochemical and PET/CT findings. The PET/CT improvement was superior in liver metastases than in other tissues. SUV tumor/non-tumor ratio performed better than SUV alone; the site for the reference ROI was the muscle tissue of the supracetabular region. The case with complete response was documented by PET after the first treatment. Conclusions Radiolabelled somatostatin analogs therapy is very promising. 68Ga-DOTATOC PET/CT is useful in pts selection and treatment monitoring. Further investigations are necessary to evaluate the appropriate timing of PET during therapy.